EMA Referral Types Explained: Article 20, Article 31, Article 107i and Article 30

Introduction

An EU referral is not a single generic regulatory procedure. The word referral describes the fact that a medicinal-product issue has been brought into a formal European procedure; the legal basis determines why that has happened, which products can be within scope, which scientific committee is responsible, and how the regulatory outcome is subsequently established and implemented.

For pharmacovigilance and regulatory professionals, four legal bases are particularly important: Article 20 of Regulation (EC) No 726/2004, Article 31 of Directive 2001/83/EC, Article 107i of Directive 2001/83/EC, and Article 30 of Directive 2001/83/EC. They are related, but they do not solve the same regulatory problem.

Article 20 has a specific pharmacovigilance application for centrally authorised medicinal products. Article 31 provides a Union-interest referral mechanism and, when used for pharmacovigilance, can encompass authorised medicines across different authorisation routes. Article 107i provides the urgent Union procedure for specified situations in which urgent regulatory action is being considered on the basis of pharmacovigilance data. Article 30 addresses a different problem: divergence between national marketing authorisations and the resulting need for harmonisation.

The distinction matters because the same safety topic can lead to different regulatory pathways depending on the authorisation status of the products, the legal trigger, the urgency and the question that the Union procedure is being asked to resolve.

A useful way to read a referral is therefore not to begin with the active substance or with the seriousness of the adverse event. Begin with the legal basis and the regulatory problem.

This article uses that approach. It first establishes the conceptual differences between the four mechanisms and then follows each procedure through its trigger, scope, scientific assessment and regulatory consequences.

1. Why the Legal Basis Matters

The EU referral system is sometimes described as though every referral follows the same sequence: a safety concern is identified, PRAC assesses it, and a European regulatory decision follows. That description is too broad for professional use.

There are several Union referral mechanisms, and their legal bases determine important elements of the procedure. A referral can concern pharmacovigilance, quality, efficacy or other regulatory matters. Even among safety procedures, the appropriate mechanism depends on whether the medicines are centrally or nationally authorised and whether the statutory conditions for an urgent procedure are met.

The legal basis therefore helps answer several practical questions:

This is why the phrase “EMA referral” is not, by itself, a sufficient regulatory description. The legal basis should be identified before interpreting the procedure.

2. The Four Mechanisms at a Glance

The four mechanisms can first be separated by the regulatory problem they are designed to address.

This table is intentionally simplified. The precise legal conditions must be read from the applicable legislation and the procedure-specific documentation.

The most important point is that Article 30 is not simply another pharmacovigilance referral, while Article 107i is not merely a faster version of an ordinary Article 31 referral. Likewise, Article 31 should not be treated as a procedure reserved only for nationally authorised medicines: centrally authorised products can be within its scope when the legal conditions require a Union procedure under Article 31.

3. Article 20 Pharmacovigilance Procedures

3.1 Legal basis and regulatory purpose

An Article 20 pharmacovigilance procedure follows Article 20 of Regulation (EC) No 726/2004.

EMA's current procedural guidance states that, when initiated as a result of the evaluation of pharmacovigilance data, Article 20 applies to medicinal products authorised through the centralised procedure only. The same Article 20 provision also has a non-pharmacovigilance application for centrally authorised medicines when the initiating data concern matters such as quality or efficacy rather than pharmacovigilance. citeturn0search0turn0search5

That distinction is important. “Article 20” is not synonymous with “pharmacovigilance referral”. The scientific source of the concern determines whether the Article 20 pharmacovigilance or non-pharmacovigilance pathway applies.

For the pharmacovigilance pathway, the essential regulatory situation is:

A pharmacovigilance issue concerning centrally authorised medicinal product(s) requires action to be considered within the Union regulatory framework.

Article 20 therefore occupies a specific place in the centralised system. It is not the general mechanism for every EU-wide safety issue.

3.2 Who initiates it?

An Article 20 pharmacovigilance procedure can be initiated only by the European Commission. An MAH cannot independently trigger the Article 20 pharmacovigilance procedure. The Commission refers the safety matter to EMA and requests a CHMP opinion based on a PRAC recommendation. citeturn0search0

This is an important operational distinction from Article 31 pharmacovigilance, for which an MAH can be an initiator under the applicable framework.

A Member State can, where urgent action is essential to protect public health, suspend use of a centrally authorised medicinal product in its territory pending a definitive Union decision. Where such action is taken on the Member State's own initiative, the Commission is informed and an Article 20 pharmacovigilance procedure is initiated if one is not already ongoing. citeturn0search0

The national protective action and the subsequent Union procedure should not be confused. The former is an immediate protective mechanism; the latter provides the Union-level regulatory assessment and decision-making pathway.

3.3 Which products can be included?

The defining scope limitation is that an Article 20 pharmacovigilance procedure concerns centrally authorised medicinal products.

The scope can extend beyond one product. EMA notes that an Article 20 pharmacovigilance procedure can concern a specific medicinal product, a range of products containing the same active substance, or a therapeutic class. However, where the relevant range or class includes nationally authorised products as well as centrally authorised products, the appropriate Union procedure is an Article 31 pharmacovigilance referral or, where applicable, an Article 107i urgent Union procedure. citeturn0search0

This creates an important practical rule for portfolio assessment:

The presence of a centrally authorised product does not mean that Article 20 automatically covers all EU products containing the same active substance. The authorisation routes of the products within the safety question matter.

3.4 PRAC and CHMP

For an Article 20 pharmacovigilance procedure, PRAC performs the pharmacovigilance assessment and adopts a recommendation. Because the affected medicines are centrally authorised, the recommendation proceeds to CHMP, which adopts the relevant opinion. citeturn0search0turn0search7

The committee sequence can therefore be represented as:

European Commission
        ↓
Article 20 PhV procedure
        ↓
PRAC assessment
        ↓
PRAC recommendation
        ↓
CHMP opinion
        ↓
European regulatory decision

The scientific recommendation and opinion should not be confused with the final legally operative Union decision.

4. Article 31 Pharmacovigilance Referrals

4.1 Legal basis and Union interest

An Article 31 pharmacovigilance referral follows Article 31 of Directive 2001/83/EC and applies when the interests of the Union are involved and the procedure is initiated as a result of the evaluation of pharmacovigilance data concerning authorised medicinal product(s). EMA's procedural guidance distinguishes this from Article 31 non-pharmacovigilance referrals, which concern matters such as quality or efficacy. citeturn0search4turn0search6

The expression “interests of the Union” is therefore central to the legal character of the procedure. It should not be converted into an invented numerical threshold. It is a regulatory and legal concept concerning the need for Union-level consideration, particularly in relation to public-health interests and the functioning of the Union medicines system.

The pharmacovigilance question and the legal trigger should be kept separate:

• Scientific question: what does the pharmacovigilance evidence indicate about the medicine and its benefit-risk balance?
• Legal question: why does the matter require consideration through the Article 31 Union procedure?

The two questions interact, but they are not the same question.

4.2 Who can initiate it?

An Article 31 pharmacovigilance referral can be initiated by a Member State competent authority, the European Commission or a marketing authorisation holder. The initiating party refers the matter to PRAC through the procedure established for the referral. citeturn0search4

The MAH's ability to initiate a referral should not be misunderstood as unilateral control over the scope of the Union procedure. EMA explains that the Member State concerned or the Commission identifies the question to be referred; an MAH seeking a referral should therefore engage with a Member State or the Commission to establish the Union interest and the appropriate question. citeturn0search4

This is a useful distinction between requesting or initiating a regulatory mechanism and defining the formal regulatory question that the committee will assess.

4.3 Which products can be included?

Article 31 pharmacovigilance is not restricted to nationally authorised products. It can include centrally authorised medicines and nationally authorised medicines, including products authorised through mutual recognition and decentralised procedures, when they fall within the scope of the referral. citeturn0search4

This broader scope is one of the principal reasons Article 31 exists as a distinct mechanism from Article 20 pharmacovigilance.

The referral may concern a particular medicinal product, a range of medicinal products containing the same active substance, or a therapeutic class. The MAH does not choose whether a product falls within the final scope merely because it is not the product that originally generated the concern. Inclusion follows the defined safety issue and referral scope. citeturn0search4

4.4 PRAC, CHMP and CMDh

PRAC performs the pharmacovigilance assessment. The subsequent committee pathway depends on the authorisation status of the products within scope.

Where at least one centrally authorised product is included, the final PRAC recommendation is sent to CHMP for adoption of an opinion. Where only nationally authorised products are included, including products authorised through MRP or DCP, the PRAC recommendation is sent to CMDh, which reaches a position. citeturn0search4

The basic pathway is therefore:

Article 31 PhV referral
          ↓
      PRAC assessment
          ↓
    PRAC recommendation
          ↓
   +------+------+
   |             |
   v             v
 CHMP          CMDh
 if CAP        if only NAPs
   |             |
   v             v
Opinion        Position

This is one of the most useful procedural distinctions for regulatory professionals. The authorisation route of the affected products determines the committee pathway after the PRAC assessment.

5. Article 20 and Article 31: The Core Distinction

The two procedures are best distinguished by scope and legal context, rather than by an assumed difference in seriousness.

The most common conceptual error is to describe Article 31 as the “national-product version” of Article 20. That is too simplistic. Article 31 can include centrally authorised medicines; its distinguishing characteristic is its Union-interest legal basis and broader ability to encompass affected authorised products.

6. Article 107i: The Urgent Union Procedure

Article 107i of Directive 2001/83/EC establishes a separate mechanism for urgent Union action arising from pharmacovigilance. EMA describes it as the urgent Union procedure and maintains a distinct procedural framework and timetable for it. citeturn0search9turn0search3

The defining feature is not merely that the safety issue is serious. The procedure is linked to the statutory circumstances in which urgent regulatory action is being considered.

This distinction is important because “urgent” is a procedural and regulatory characteristic, not a synonym for “high severity” in ordinary clinical language.

Article 107i should therefore be read as a mechanism for situations in which the pharmacovigilance concern falls within the urgent-action criteria of the legislation, rather than as a general fast-track option available whenever an MAH or authority considers a safety issue important.

6.1 The relationship with Article 31

Article 31 pharmacovigilance and Article 107i are closely related because both operate within the pharmacovigilance referral framework and can involve products across authorisation routes. They are nevertheless not interchangeable.

EMA's Article 31 guidance states that an Article 31 pharmacovigilance referral should be initiated where the interests of the Union are involved and none of the criteria listed in Article 107i are met. Where an Article 107i criterion is met, the urgent Union procedure applies. citeturn0search4

This provides a particularly useful decision point:

Pharmacovigilance concern requiring Union-level action
                         ↓
              Do Article 107i criteria apply?
                    /              \
                  YES              NO
                   ↓                ↓
              Article 107i      Article 31 PhV

The distinction is therefore not simply one of speed. The legal criteria determine the appropriate route.

6.2 Committee pathway

PRAC performs the safety assessment in an Article 107i procedure. Following the PRAC recommendation, the pathway again depends on the products within scope. If at least one centrally authorised product is included, the recommendation goes to CHMP for an opinion. If only nationally authorised products are included, CMDh reaches a position. citeturn0search9

The urgent Union procedure therefore retains the fundamental distinction between scientific pharmacovigilance assessment and the subsequent regulatory route.

7. Article 30: Harmonising Divergent National Authorisations

Article 30 of Directive 2001/83/EC addresses a different regulatory problem: divergence between national marketing authorisations.

The legislation provides a Union referral mechanism where multiple applications for a particular medicinal product have resulted in divergent decisions by Member States concerning the authorisation, suspension or revocation of the product. The matter is referred to CHMP for the applicable Union procedure. citeturn0search2

EMA describes Article 30 referrals as a mechanism used when Member States have adopted different decisions over time for medicines, including differences in areas such as indications, contraindications or posology, and a Union-level harmonisation is needed. citeturn0search10

This leads to the central distinction:

Article 30 is fundamentally a harmonisation referral, not a pharmacovigilance referral.

A safety issue may contribute to divergence or may be part of the scientific material considered in an individual procedure, but the defining regulatory problem is the existence of divergent national authorisations and the need to establish a harmonised Union position.

7.1 The question Article 30 is trying to answer

The conceptual question in Article 30 is different from the question asked in an ordinary safety referral.

A safety referral asks, in substance:

What does the available evidence mean for the safety and benefit-risk balance of the affected medicine, and what regulatory action is required?

An Article 30 referral asks instead:

Why do different Member States have materially different regulatory positions for the same medicine, and what common regulatory position should be established?

The distinction matters when interpreting the scientific documents. An Article 30 assessment should be read as an exercise in establishing a coherent Union regulatory position, not automatically as evidence that a new pharmacovigilance signal has triggered the procedure.

7.2 Examples of divergence

National product information can diverge in clinically important areas, including:

• therapeutic indication;
• contraindications;
• posology;
• warnings and precautions;
• other conditions of use.

The existence of such divergence does not mean that the national authorities acted improperly. Divergence can develop historically because different national procedures, scientific assessments, evidence packages or regulatory decisions occurred at different times.

Article 30 provides a mechanism through which the Union system can reassess the relevant evidence and establish a harmonised position where the legal conditions for the referral are met.

7.3 Who can initiate Article 30?

Article 30 can be initiated through the parties and circumstances specified in Directive 2001/83/EC, including a Member State, the European Commission, the applicant or the marketing authorisation holder. The matter is referred to CHMP under the Article 30 framework. citeturn0search2

The role of the MAH is particularly relevant where a legacy portfolio contains materially divergent national product information. However, the formal regulatory scope and scientific questions remain matters of the Union procedure rather than matters that the MAH can define unilaterally.

8. The Four Procedures Compared

The four mechanisms can now be placed on a single conceptual map.

The table is a working aid, not a substitute for the legislation. The exact scope of an individual referral must always be taken from its initiating document and applicable legal provisions.

9. A Practical Rule for Identifying the Referral Type

When a new referral appears in a regulatory intelligence system, a QPPV or regulatory professional can work through the following questions in sequence.

Question 1: Is the procedure pharmacovigilance-driven?

If no, Article 20 or Article 31 may still be relevant, but the non-pharmacovigilance pathway must be considered. Article 30 may also be relevant where the underlying problem is divergence between national authorisations.

If yes, continue.

Question 2: Are only centrally authorised products concerned?

If the procedure is a pharmacovigilance matter and only centrally authorised products are concerned, Article 20 may be the appropriate mechanism.

If nationally authorised products also need to be included, Article 20 pharmacovigilance is not the mechanism for the broader product population.

Question 3: Do the Article 107i criteria apply?

If the statutory criteria for the urgent Union procedure are met, Article 107i applies rather than an ordinary Article 31 pharmacovigilance referral. EMA's guidance explicitly makes this distinction. citeturn0search4

Question 4: Is the underlying regulatory problem divergence between national authorisations?

If the central problem is divergent national decisions for the same medicine and the need to harmonise them, Article 30 should be considered.

This gives a useful conceptual decision tree:

                 EU referral issue
                       ↓
             What is the legal problem?
                       ↓
        +--------------+---------------+
        |                              |
        v                              v
 Pharmacovigilance               Other regulatory issue
        |                              |
        v                              +----> Consider Article 30
 Are only CAPs concerned?
     /          \
   YES           NO
    |             |
 Article 20       ↓
                Article 107i criteria met?
                  /              \
                YES              NO
                 |                |
             Article 107i    Article 31 PhV

This is a conceptual screening tool. It does not replace examination of the actual statutory provisions or referral notification.

10. Why These Distinctions Matter for an MAH

For an MAH, the referral type determines the regulatory environment in which the company must respond.

The company needs to understand at least:

• the legal basis;
• the products and presentations within scope;
• the formal questions referred;
• the committee responsible for the assessment;
• the applicable submission timetable;
• the evidence required from the MAH;
• the possible regulatory consequences;
• the product-information implications;
• the implementation requirements after the procedure.

The distinction is especially important for organisations with both centrally and nationally authorised portfolios.

A safety issue concerning a CAP-only portfolio may follow Article 20. A broader active-substance issue involving both CAPs and NAPs may require Article 31 or Article 107i. A legacy portfolio with materially divergent national product information may instead raise an Article 30 issue.

The regulatory organisation therefore needs to identify the procedure before designing its internal response structure.

11. Why These Distinctions Matter for the QPPV

For the QPPV, referral classification has a direct bearing on pharmacovigilance governance.

The QPPV should be able to determine whether the procedure is:

• an ordinary safety assessment;
• a formal Union pharmacovigilance referral;
• an urgent Union procedure; or
• a non-pharmacovigilance harmonisation procedure with potential safety implications.

That classification affects how the issue is connected to the company's safety surveillance, signal management, risk-management activities, regulatory strategy and implementation controls.

It also affects how the organisation reconstructs the evidence trail. A referral is not an isolated regulatory event. It can become a major lifecycle event requiring coordinated action across pharmacovigilance, regulatory affairs, medical, clinical, quality, safety science, labelling and local affiliates.

For inspection purposes, the organisation should be able to explain not only what the final referral outcome was, but also how it identified the referral, assessed its relevance to the products under its responsibility, responded to the scientific questions, and implemented the resulting regulatory measures.

6.2 The scope of an urgent Union procedure

Article 107i can encompass medicinal products affected by the safety issue with valid marketing authorisations in the European Economic Area, regardless of whether those authorisations were granted nationally or through the centralised procedure. Where the safety issue concerns only centrally authorised medicinal products, the Article 20 pharmacovigilance procedure applies instead. citeturn1search0

The scope can extend to a particular medicinal product, a range of products containing the same active substance, or products belonging to a therapeutic class. The scope is established by the safety concern and the triggering notification, rather than by the preference of individual marketing authorisation holders. citeturn1search0

This is important for portfolio governance. An MAH cannot assume that its product is outside the procedure because another company's product generated the original concern. Conversely, the presence of a product in the same therapeutic class does not by itself establish inclusion. The actual referral scope must be read.

6.3 Who can initiate Article 107i?

An urgent Union procedure can be initiated by a Member State competent authority or the European Commission. An MAH cannot itself trigger the Article 107i procedure. The initiator circulates the notification to EMA, the Member States and the Commission, identifying the safety concern and the regulatory action under consideration. citeturn1search0

This is an important difference from Article 31 pharmacovigilance. An MAH may provide information and may be the subject of the regulatory consequences, but it does not have the same initiating role under Article 107i.

A Member State can also take urgent protective action where necessary to protect public health, including suspension of a marketing authorisation and prohibition of use in its territory pending the definitive decision, with the required notification to the Commission, EMA and other Member States. citeturn1search0turn0search6

The existence of a national interim measure does not mean that the national authority has completed the Union assessment. It is a protective measure operating within the urgent Union framework.

6.4 What makes Article 107i genuinely different?

The legislation identifies specific circumstances that distinguish Article 107i from an ordinary Article 31 pharmacovigilance referral. These include consideration of suspension or revocation of a marketing authorisation, prohibition of supply, refusal of renewal, and specified situations involving a new contraindication, reduction in recommended dose or restriction of indications where the medicine is authorised in more than one Member State. citeturn1search0turn0search6

The important point is that the statutory trigger is linked to the regulatory action being contemplated.

It is therefore inappropriate to create an informal rule such as “serious safety signal = Article 107i”. A serious safety concern may instead be addressed through Article 31 if the statutory urgent-action conditions are not met but the interests of the Union are involved.

6.5 The PRAC assessment

Once an Article 107i procedure has been triggered, the matter is considered by PRAC. EMA publishes the procedure information and identifies the safety issue, the affected products and the mechanisms through which relevant information can be submitted. citeturn1search0

The MAH's task is not simply to repeat its routine pharmacovigilance position. The company must assemble the evidence relevant to the specific questions raised in the procedure, including information that may affect the benefit-risk assessment and the regulatory action under consideration.

Because the procedure is urgent, the opportunity to submit evidence is structured around the published timetable. EMA notes that MAHs, healthcare professionals and the public can submit relevant information, although stakeholder submissions other than those required from MAHs are not themselves a mandatory step. citeturn1search0

The resulting PRAC recommendation applies to the marketing authorisations within the scope of the procedure. The subsequent CHMP or CMDh pathway depends on the products concerned and the applicable legal framework. citeturn1search0

7. Article 30: The Harmonisation Referral

Article 30 of Directive 2001/83/EC addresses a fundamentally different regulatory problem: divergent national decisions concerning a medicinal product.

EMA describes an Article 30 referral as a “harmonisation” referral. It applies where Member States have adopted divergent decisions concerning the authorisation of a nationally authorised medicinal product, including differences in matters such as indications, posology, contraindications or warnings. It can also apply to divergent decisions concerning suspension or revocation. citeturn1search1

The central regulatory question is therefore not primarily:

“What new safety signal has emerged?”

It is:

“Why do different national authorisations contain different regulatory positions, and what harmonised position should apply?”

A safety issue can be relevant to the scientific justification for harmonisation, but the defining characteristic of Article 30 is divergence of national regulatory decisions.

7.1 Article 30(1) and Article 30(2)

The Article 30 mechanism contains more than one route to harmonisation.

Under Article 30(1), a referral may be initiated where divergent decisions have been adopted by Member States concerning the authorisation, suspension or revocation of a particular medicinal product. The referral can be initiated by a Member State, the European Commission or an MAH/applicant where the statutory conditions are met. citeturn1search1

Article 30(2) provides a further harmonisation mechanism for medicines authorised in the EU. EMA explains that CMDh prepares an annual list of products proposed for harmonisation, taking account of Member State proposals, which is forwarded to the European Commission. An Article 30(2) procedure can then be initiated for products on that list by the Commission or a Member State in accordance with the applicable framework. citeturn1search1

The distinction matters because not every Article 30 referral originates from an acute disagreement between two authorities over a current application. Some procedures address accumulated divergence in national authorisations that has persisted across Member States.

7.2 Who initiates an Article 30 referral?

An Article 30 referral can be initiated by national competent authorities, the European Commission or the MAH/applicant, subject to the conditions of the relevant provision. The matter is referred to CHMP through the formal notification process. citeturn1search1

EMA recommends that an MAH/applicant considering initiating an Article 30(1) referral seek a pre-referral meeting with the Agency. This reflects the practical importance of defining the divergence and the material needed for the procedure before the formal referral begins. citeturn1search1

7.3 What is actually assessed?

CHMP is responsible for the assessment in an Article 30 referral. The Committee appoints a rapporteur and co-rapporteur(s) to assess the information and formulate the scientific basis for the opinion. citeturn1search1

The MAH/applicant is expected to provide the evidence necessary to address the divergence. Where the referral concerns divergent authorisation decisions, the MAH is also requested to provide a proposed harmonised SmPC, labelling and package leaflet. citeturn1search1

This is a particularly important difference from a pharmacovigilance referral. The regulatory work is explicitly directed toward establishing a harmonised authorised position rather than simply determining whether a safety signal is confirmed.

7.4 The importance of identifying the divergence

A good Article 30 submission begins with a precise map of the divergence.

The regulatory team should establish, for each relevant Member State:

• the authorised product name;
• marketing authorisation holder;
• strength and pharmaceutical form;
• route of administration where relevant;
• indication(s);
• posology;
• contraindications;
• warnings and precautions;
• other relevant product-information differences;
• the legal or procedural history explaining the difference.

The objective is not to produce a catalogue of national texts without analysis. The purpose is to identify which regulatory differences require scientific and regulatory harmonisation and why.

EMA's Article 30 guidance specifically requires the MAH to identify the divergent national positions and, where applicable, provide a proposed harmonised product-information package. citeturn1search1

8. The Four Procedures Compared by Trigger

The most useful way to distinguish the procedures in practice is to start with the question that caused the Union procedure.

This is a starting framework, not a substitute for checking the legislation.

A regulatory professional should then verify the authorisation status of the affected products and read the actual notification initiating the procedure.

9. The Four Procedures Compared by Committee Pathway

Committee involvement is another useful discriminator.

The table should not be interpreted as saying that committees make the final legal decision. Scientific committees produce recommendations, opinions or positions within the statutory procedure. The legally operative outcome follows the applicable legislative route.

This distinction is particularly important for Article 30. CHMP is the scientific committee responsible for the referral, but the resulting opinion is followed by the appropriate European regulatory decision-making process.

10. How a Referral Moves From Scientific Assessment to Regulatory Outcome

The precise post-assessment pathway differs by referral type, but the general principle is consistent: scientific assessment and legal implementation are separate stages.

For a pharmacovigilance referral, PRAC assesses the safety issue and adopts a recommendation. Depending on the products concerned, CHMP adopts an opinion or CMDh reaches a position. The applicable legal provisions then determine how the resulting Union position becomes operative for the affected marketing authorisations.

For Article 20 pharmacovigilance, the route is PRAC recommendation followed by CHMP opinion because the products are centrally authorised. EMA's procedural material explicitly describes this PRAC-to-CHMP sequence. citeturn0search0

For Article 31 pharmacovigilance, the route branches according to product authorisation status: CHMP where at least one centrally authorised product is included, or CMDh where only nationally authorised products are involved. citeturn0search5

For Article 30, CHMP itself performs the scientific assessment and adopts the opinion. Following the final opinion, EMA, the MAH and national competent authorities finalise the translations and submit them to the European Commission for the decision-making process. citeturn1search2

The practical lesson is that a committee conclusion is not necessarily the final legal instrument.

11. Re-examination: Why It Matters

A referral procedure can provide a mechanism for reconsidering a committee recommendation or opinion where the applicable legislation and procedural framework permit re-examination.

For example, in an Article 31 pharmacovigilance referral, an MAH may request re-examination of the PRAC recommendation within the applicable procedural period. If re-examination is requested, PRAC considers the detailed grounds and adopts a final recommendation. The final recommendation is then sent to CHMP or CMDh according to the product scope. citeturn0search5

Article 30 also provides a re-examination mechanism for the CHMP opinion. EMA's current guidance states that an MAH/applicant may notify EMA within 15 calendar days of receipt of the CHMP opinion of its intention to request re-examination and must submit detailed grounds within 60 calendar days. citeturn1search2

The important conceptual point is that re-examination is not simply an opportunity to restart the entire procedure. The grounds submitted define the scope of the re-examination, subject to the applicable legal and procedural rules. citeturn1search2

For an MAH, this means that the re-examination strategy should be prepared with the same discipline as the original response: identify the precise scientific or procedural grounds, distinguish disagreement from new evidence, and ensure that the requested reconsideration is supported by the record.

12. What the MAH Should Manage During a Referral

A referral is not a single regulatory submission owned by one department. It is a cross-functional regulatory event.

The MAH may need coordinated input from:

• pharmacovigilance;
• medical safety;
• regulatory affairs;
• clinical or epidemiology functions;
• statistics and data analysis;
• risk management;
• clinical development or medical affairs where historical evidence is relevant;
• quality or manufacturing functions if the issue has a quality dimension;
• legal or compliance functions where appropriate;
• product-information and labelling teams;
• translation and implementation teams.

The exact composition depends on the referral.

For a pharmacovigilance referral, the QPPV should have clear visibility of the safety assessment and the company's overall response. This does not mean that the QPPV personally authors every regulatory response. Rather, the pharmacovigilance system must be capable of providing a coherent, traceable and medically defensible assessment of the safety issue.

The response should connect the evidence to the regulatory question. A large dossier is not necessarily a good referral response if the evidence is not organised around the questions posed by PRAC or the relevant committee.

For an Article 30 referral, the emphasis may instead be on reconstructing national regulatory histories, explaining divergent positions and developing a scientifically justified harmonised product-information proposal. EMA explicitly asks MAHs/applicants to provide relevant information and, in cases involving divergent authorisation decisions, a proposed harmonised SmPC, labelling and package leaflet. citeturn1search1

The internal governance principle is therefore:

Build the response around the regulatory question, not around the documents that happen to be easiest to retrieve.

13. What the QPPV Should Watch Closely

For a QPPV, a referral should be treated as a high-visibility pharmacovigilance event with defined regulatory interfaces.

At minimum, the QPPV should understand:

1. the exact safety issue or regulatory question;
2. the legal basis of the referral;
3. the products and authorisation routes within scope;
4. the PRAC questions or other formal questions posed by the procedure;
5. the evidence submitted by the company;
6. the company's interpretation of the benefit-risk balance;
7. proposed risk-minimisation measures;
8. proposed changes to product information;
9. interactions with the RMP and other pharmacovigilance commitments;
10. the final recommendation, opinion or position;
11. the legally operative decision and implementation requirements;
12. subsequent monitoring of the effectiveness of the implemented measures.

The last point is especially important. A referral does not necessarily end the pharmacovigilance work when the Commission decision or national implementation is complete.

The regulatory outcome may create new monitoring requirements, revised safety specifications, additional risk-minimisation measures, changes to the RMP or changes in the way future safety information is evaluated.

A referral should therefore be incorporated into the pharmacovigilance system as a lifecycle event, not archived as a completed regulatory transaction.

14. A Practical Reading Method for an EMA Referral

When an EMA referral page is opened for the first time, the following sequence is more reliable than reading the documents chronologically.

Step 1 — Identify the legal basis

Confirm whether the procedure is Article 20, Article 31, Article 107i, Article 30 or another referral mechanism.

Step 2 — Identify the initiating problem

Determine whether the issue concerns pharmacovigilance, urgent safety action, harmonisation, quality, efficacy or another regulatory matter.

Step 3 — Identify the product scope

Determine which products, active substances, therapeutic classes and MAHs are actually within scope.

Step 4 — Identify the authorisation routes

Separate centrally authorised products from nationally authorised products and identify MRP/DCP products where relevant.

Step 5 — Identify the scientific committee

Determine whether PRAC, CHMP or CMDh has the relevant role and whether more than one committee will be involved.

Step 6 — Read the questions

The formal questions define what the committee has been asked to assess. They are often more informative than a general summary of the safety concern.

Step 7 — Read the assessment

Only after understanding the question should the scientific assessment be interpreted.

Step 8 — Read the outcome

Distinguish the PRAC recommendation, CHMP opinion, CMDh position and final legally operative decision.

Step 9 — Map implementation

Identify changes to the SmPC, package leaflet, RMP, risk-minimisation measures, safety communications and other regulatory obligations.

Step 10 — Follow the post-referral lifecycle

Confirm that the company has implemented the outcome and incorporated the new regulatory baseline into ongoing pharmacovigilance and regulatory surveillance.

This method prevents one of the most common errors in referral interpretation: reading the scientific conclusion without first understanding the legal question that the committee was asked to answer.

15. Why the Distinction Matters in Practice

Consider four hypothetical situations involving the same active substance.

Example A — CAP-only pharmacovigilance issue

A safety concern affects only centrally authorised products. The issue requires Union-level assessment but does not fall within the urgent Article 107i criteria.

The relevant pharmacovigilance mechanism is Article 20.

Example B — CAP and nationally authorised products

The same type of pharmacovigilance concern affects a centrally authorised product and nationally authorised products containing the same active substance. The issue requires Union-level assessment, but the statutory urgent-action criteria are not met.

The relevant mechanism can be Article 31 pharmacovigilance, with the committee pathway determined by the products within scope. citeturn0search0turn0search5

Example C — Urgent regulatory action

A pharmacovigilance assessment leads a Member State or the Commission to consider one of the regulatory actions specified in Article 107i, such as suspension or revocation, prohibition of supply or refusal of renewal, or the other specified urgent situations.

The relevant mechanism is Article 107i. citeturn1search0

Example D — Different national labels

The same nationally authorised medicine has materially divergent indications, contraindications, posology or warnings across Member States, and a Union-level harmonisation is required.

The relevant mechanism is Article 30. citeturn1search1

The examples demonstrate why the name of the safety issue alone cannot determine the referral type.

16. A Decision Framework for Regulatory Professionals

A practical decision tree can be reduced to four questions:

START
  |
  v
Is the issue about divergent national authorisations?
  |
 YES --------------------> Article 30
  |
 NO
  |
  v
Is the issue based on pharmacovigilance data?
  |
 NO ---------------------> Consider the applicable non-PV referral basis
  |
 YES
  |
  v
Are the products only centrally authorised?
  |
 YES
  |
  v
Do Article 107i urgent-action criteria apply?
  |
 YES --------------------> Article 107i is the relevant urgent pathway
  |
 NO ---------------------> Article 20 pharmacovigilance

If products are not limited to CAPs:
  |
  v
Do Article 107i criteria apply?
  |
 YES --------------------> Article 107i
  |
 NO ---------------------> Article 31 pharmacovigilance

This is deliberately a conceptual decision framework. The final determination must be made from the applicable legislation and the actual facts of the procedure.

It also illustrates an important point: Article 107i is assessed as a statutory branch of the pharmacovigilance referral framework, not merely as a choice made according to perceived urgency.

17. The Regulatory Significance of the Referral Type

The referral type affects more than the name displayed on an EMA webpage.

It determines the legal route through which a safety or regulatory issue is considered, the committee structure, the products that can be included, the parties involved, and the way the resulting conclusion becomes operative.

For an MAH, this affects submission strategy and governance.

For a QPPV, it affects pharmacovigilance oversight and the interpretation of the regulatory consequences.

For regulatory affairs, it determines which legal instruments and implementation pathways must be followed.

For inspectors, the distinction can help reconstruct whether the company's actions were aligned with the actual legal procedure rather than with an informal understanding of “an EMA referral”.

A mature regulatory organisation should therefore maintain a procedure-level record that distinguishes:

• the initiating legal basis;
• the formal trigger;
• the scope;
• the scientific assessment;
• the committee recommendation/opinion/position;
• the final legal decision;
• implementation;
• post-implementation monitoring.

That record creates a defensible bridge between the pharmacovigilance system and the regulatory system.

Step 6 — Read the questions

The formal questions define what the committee has been asked to assess. They should be separated from the broader scientific background presented in the assessment report.

A useful working document is a question-to-evidence matrix:

This prevents the response from becoming a general review of the medicine when the committee has asked a narrower regulatory question.

Step 7 — Follow the procedural documents

Read the referral notification, assessment reports, PRAC recommendation, CHMP opinion or CMDh position, and final decision in that order where applicable.

Each document answers a different question:

• Referral notification: why the procedure exists and what has been referred;
• assessment report: how the scientific evidence was evaluated;
• PRAC recommendation: what PRAC concluded from the pharmacovigilance assessment;
• CHMP opinion: the relevant scientific conclusion for the centrally authorised product pathway, where applicable;
• CMDh position: the corresponding position for the nationally authorised pathway, where applicable;
• Commission decision: the legally operative Union outcome.

The documents should not be treated as interchangeable summaries of the same information.

Step 8 — Identify the implementation consequence

The final question is not simply “what did the committee conclude?” It is:

What legally and operationally changes as a result of that conclusion?

Depending on the procedure and outcome, consequences may include changes to the product information, risk-minimisation measures, restrictions on use, additional pharmacovigilance activities, or changes to the marketing authorisation itself.

The exact consequence must be established from the final regulatory instrument rather than inferred from the scientific recommendation alone.

15. Worked Examples: How the Legal Basis Changes the Interpretation

Example 1 — Safety issue involving only centrally authorised products

A pharmacovigilance concern affects several centrally authorised products containing the same active substance. There are no nationally authorised products within the scope of the issue.

The relevant pharmacovigilance referral mechanism is Article 20.

The important facts are the centralised status of the affected products and the pharmacovigilance nature of the issue. PRAC performs the safety assessment and the recommendation proceeds to CHMP.

The fact that the issue is serious does not itself make Article 107i applicable. The statutory conditions for the urgent Union procedure must separately be satisfied.

Example 2 — Same safety concern, but nationally authorised products are also affected

Suppose the same active substance is present in both centrally authorised and nationally authorised medicines and the Union safety concern extends to both groups.

Article 20 cannot simply be expanded to include the nationally authorised products. A pharmacovigilance Article 31 procedure or, where the statutory urgent-action criteria are met, an Article 107i procedure may be appropriate.

This example illustrates why authorisation status must be established before choosing the legal route.

Example 3 — Urgent action is being considered

Assume pharmacovigilance information raises a concern and the regulatory authorities are considering an action falling within the urgent-action circumstances specified by Article 107i.

The issue should not be treated as an ordinary Article 31 referral merely because both procedures can involve nationally authorised medicines. The statutory Article 107i criteria determine the route.

The urgent procedure has its own timetable and procedural framework. EMA currently publishes a separate timetable for Article 107i procedures. The published timetable should be used for the live procedure rather than relying on a generic referral timeline.

Example 4 — Different national product information for the same medicine

Imagine that a medicine has been authorised nationally in several Member States for many years and that the authorised indications, contraindications or warnings differ between countries.

There may be no newly emerging pharmacovigilance signal at all. The regulatory problem is the divergence itself.

This is the type of situation for which an Article 30 harmonisation referral can be relevant.

The scientific work is directed toward establishing the appropriate harmonised regulatory position. CHMP assesses the matter and adopts an opinion. The resulting Union decision then provides the basis for implementation in the affected national authorisations.

The example demonstrates why it is incorrect to classify every referral involving safety-related wording as a pharmacovigilance referral.

16. Common Misconceptions

Misconception 1: “An EMA referral is always a safety referral.”

It is not.

EU referral procedures cover different regulatory problems. Article 30 is principally a harmonisation mechanism, while Article 31 and Article 20 can also have non-pharmacovigilance applications. The legal basis and initiating issue must be established first.

Misconception 2: “Article 31 is only for nationally authorised medicines.”

It is not.

An Article 31 pharmacovigilance referral can include centrally authorised medicines. The important distinction from Article 20 is the legal framework and scope, not a simple CAP-versus-NAP division.

Misconception 3: “Article 107i just means a serious Article 31.”

It does not.

Article 107i has specific statutory circumstances concerning urgent regulatory action. The route is determined by the legal criteria, not by an informal assessment of how serious a safety issue appears.

Misconception 4: “PRAC makes the final regulatory decision.”

PRAC performs the pharmacovigilance assessment and adopts a recommendation within the applicable procedure. The subsequent CHMP, CMDh and European Commission stages have distinct functions.

Misconception 5: “CHMP approval is the same thing as the Commission decision.”

It is not.

A CHMP opinion is a scientific committee opinion within the Union regulatory framework. The legally binding Commission decision is a separate stage where the legislation provides for one.

Misconception 6: “Article 30 means that the medicine is unsafe.”

It does not.

Article 30 addresses divergence between national marketing authorisations. A safety issue may be part of the scientific explanation for divergence, but divergence itself is the defining regulatory problem.

Misconception 7: “The product that generated the signal is automatically the only product affected.”

It is not.

The scope of a referral is determined by the formal procedure and the regulatory question. Other products containing the same active substance, products in a relevant therapeutic class, or products with different authorisation routes may fall within scope when the procedure so provides.

Misconception 8: “The committee recommendation is the end of the procedure.”

It is not.

The regulatory consequences must still be established and implemented. For pharmacovigilance procedures, the relevant product information, risk-minimisation measures, RMP and pharmacovigilance activities may require further action after the scientific conclusion.

17. Inspection Considerations

An inspection involving a referral is unlikely to be satisfied by evidence that the company received the final regulatory decision. Inspectors may reasonably expect the pharmacovigilance system to demonstrate how the safety issue was identified, assessed, escalated, responded to and subsequently monitored.

The precise inspection scope will depend on the inspection objective, but a mature system should be able to reconstruct the regulatory history.

Useful evidence includes:

• the original safety concern and its source;
• signal or issue-management records;
• internal medical and pharmacovigilance assessments;
• the referral notification;
• the questions submitted by the committee;
• company responses and supporting analyses;
• review and approval records;
• PRAC recommendations and relevant committee documents;
• CHMP opinions or CMDh positions where applicable;
• the European Commission decision where applicable;
• implemented product-information changes;
• RMP updates and commitments;
• communications to healthcare professionals where required;
• evidence of implementation across affected Member States;
• subsequent monitoring of the regulatory measures.

The important inspection principle is traceability.

An inspector should be able to follow the chain:

Safety information
      ↓
Internal assessment
      ↓
Regulatory escalation
      ↓
Referral
      ↓
Company response
      ↓
Scientific conclusion
      ↓
Legal decision
      ↓
Implementation
      ↓
Post-implementation monitoring

The exact records and responsibilities depend on the applicable pharmacovigilance system requirements and the individual procedure.

A second principle is consistency. The company's referral response, RMP, signal-management documentation, safety database assessment and subsequent product-information implementation should not contain unexplained contradictions about the same safety issue.

18. QPPV Perspective: Why Correct Classification Matters

For the QPPV, correctly identifying the referral type is more than a regulatory terminology exercise.

The legal basis affects the procedural pathway, the committees involved, the products within scope, the timetable and the possible regulatory consequences. Misclassification at the beginning can therefore lead to inappropriate assumptions later in the process.

A QPPV should be able to answer, without ambiguity:

What is the legal basis, why was this procedure initiated, which products are within scope, what questions are being assessed, what has the company submitted, what did the scientific committees conclude, what legally changed, and how has that change been incorporated into the pharmacovigilance system?

That is the practical meaning of understanding referral types.

The QPPV does not need to become the company's legal counsel or procedural specialist for every referral. The role is instead to ensure that the pharmacovigilance system is accurately represented, that safety evidence is appropriately assessed and governed, and that the resulting regulatory requirements are incorporated into the system and maintained.

19. A Compact Decision Framework

When confronted with a new EU referral, the following sequence provides a useful first assessment.

START
  |
  v
Is the issue a pharmacovigilance matter?
  |
  +---- NO ----> Consider the applicable non-PV referral basis
  |
 YES
  |
  v
Are only centrally authorised medicines affected?
  |
  +---- YES ----> Article 20 PhV may apply
  |
  NO / mixed scope
  |
  v
Do the statutory Article 107i urgent-action criteria apply?
  |
  +---- YES ----> Article 107i
  |
  NO
  |
  v
Are the interests of the Union involved?
  |
  +---- YES ----> Article 31 PhV

For a referral concerning divergent national authorisations, the starting point is different:

Divergent national authorisations or decisions
                 |
                 v
        Article 30 framework
                 |
                 v
              CHMP
                 |
                 v
      Harmonised regulatory position

This is a conceptual decision aid, not a substitute for legal assessment. A live procedure should always be classified from the formal notification and applicable legislation.

20. Key Takeaways

The four legal bases can be remembered through the regulatory problem they address:

The distinctions are more precise than those shorthand descriptions suggest.

Article 20 pharmacovigilance is restricted to centrally authorised medicines. Article 31 pharmacovigilance can include centrally and nationally authorised medicines when the Union-interest conditions are met. Article 107i has specific statutory urgent-action criteria and its own procedural framework. Article 30 addresses divergence between national authorisations and is therefore not simply another safety-referral mechanism.

For regulatory professionals, the most reliable approach is to identify the legal basis, trigger, product scope, authorisation route, committee pathway and final legal instrument before interpreting the scientific conclusions.

For the QPPV, the work continues beyond the committee conclusion. The regulatory outcome must be translated into the pharmacovigilance system, product information, risk management and ongoing safety oversight as applicable.

References

Primary legislation

1. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use, as amended. In particular, Articles 30, 31 and 107i–107k and the associated referral provisions. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32001L0083

2. Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004, as amended, laying down Union procedures for the authorisation, supervision and pharmacovigilance of medicinal products for human use and establishing a European Medicines Agency. In particular, Article 20 and the provisions governing the centralised system. https://eur-lex.europa.eu/eli/reg/2004/726/oj

European Medicines Agency

1. European Medicines Agency. Questions and answers: Article 20 pharmacovigilance procedures. Current procedural guidance on Article 20 pharmacovigilance procedures, including scope, initiation, PRAC recommendation and CHMP opinion. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/referral-procedures-human-medicines/questions-answers-article-20-pharmacovigilance-procedures

2. European Medicines Agency. Questions and answers: Article 31 pharmacovigilance referrals. Current procedural guidance on Article 31 pharmacovigilance referrals, including Union interest, initiation, scope, PRAC assessment and CHMP/CMDh pathways. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/referral-procedures-human-medicines/questions-answers-article-31-pharmacovigilance-referrals

3. European Medicines Agency. Questions and answers: Urgent Union procedures (Article 107i). Current procedural guidance concerning Article 107i urgent Union procedures. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/referral-procedures-human-medicines/questions-answers-urgent-union-procedures-article-107i

4. European Medicines Agency. Questions and answers: Article 30 referral procedures. Current procedural guidance concerning Article 30 harmonisation referrals. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/referral-procedures-human-medicines/questions-answers-article-30-referral-procedures

5. European Medicines Agency. Referral procedures: regulatory and procedural guidance. Central index for referral-related guidance, including Article 20, Article 30, Article 31 and Article 107i procedures and current procedural timetables. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/referral-procedures-human-medicines/referral-procedures-regulatory-procedural-guidance

6. European Medicines Agency. Procedural timetables. Current referral timetables, including separate timetables for Article 20/Article 31 pharmacovigilance referrals and Article 107i urgent Union procedures. https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/submission-dates/procedural-timetables

7. European Medicines Agency. Referral procedures for human medicines. Overview of Union referral mechanisms and their regulatory context. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/referral-procedures-human-medicines

8. European Commission. Notice to Applicants, Volume 2A, Chapter 3 — Union Referral Procedures. Procedural framework relevant to Union referral procedures. https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-2_en

9. European Commission. Notice to Applicants, Volume 2A, Chapter 6 — Decision-making procedure for the adoption of Commission Decisions. Relevant to the transition from scientific opinion to Commission decision. https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-2_en

Regulatory Note

This article is an educational explanation of the principal EU referral mechanisms relevant to human medicines. It is not legal advice and does not replace the applicable legislation, current EMA procedural guidance, CMDh guidance, national requirements or the formal documents governing an individual referral.

The article deliberately distinguishes legal requirements, scientific assessment, regulatory procedure and implementation practice. A general description of a referral mechanism should not be used to infer the exact requirements of a live procedure without checking the procedure-specific documentation.

EU medicines legislation and procedural guidance are amended and updated over time. The references above should therefore be checked against their current versions when the article is used for an active regulatory matter. EMA's referral guidance and procedural-timetable pages are maintained separately from the underlying legislation and should be read as procedural guidance rather than as substitutes for the legal text.

In particular, the applicable legal basis should be established from the formal referral notification and the current legislation. The scope of products, questions referred, committee responsibilities, procedural timetable and final regulatory consequences should then be established from the documents for that individual procedure.

Where a scientific committee recommendation, CHMP opinion or CMDh position is followed by a European Commission decision, the legally operative effect derives from the applicable legal instrument and not merely from the committee document. Similarly, implementation of a regulatory outcome should be verified against the final decision and applicable implementation guidance rather than inferred solely from the scientific assessment.

The article uses the terms centrally authorised medicinal product (CAP) and nationally authorised medicinal product (NAP) in their established regulatory sense. NAPs may include products authorised through national, mutual-recognition and decentralised procedures, depending on context.

Finally, Article 20, Article 31, Article 107i and Article 30 should not be treated as interchangeable labels for an “EMA safety review”. Correct classification is a prerequisite for correctly understanding the regulatory pathway, and the formal legal and procedural documents always take precedence over this educational summary.